Combined antiretroviral therapy appears to have cut the average mortality rate by half in HIV patients followed for an average of more than three years, researchers report in the January 2nd issue of AIDS.
The CD4 cell count at baseline appeared to influence the amount of benefit seen with combined antiretroviral therapy. In subjects with counts less than 100 cells/microliter, therapy cut the risk of death by 71%, whereas in those with counts of 500 cells/microliter or higher, therapy reduced the risk by only 23%. The estimated hazard ratio also varied with years since initiation of combined therapy, ranging from 0.57 for less than 1 year since initiation to 0.21 for 5 years or more. Combined therapy, the authors note, "halved the mortality rate of HIV-infected individuals in developed countries, and the absolute reduction in mortality was stronger in those with worse prognosis at the start of follow-up." The finding, the team concludes, "demonstrates the benefits of being treated even at the most advanced stages of immunosuppression."
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||RESEARCH & TECHNOLOGY|
|Article Type:||Brief article|
|Date:||Jan 11, 2010|
|Previous Article:||Alzheimer's disease may be better treated with a cocktail of therapies that limit production of plaque that impairs the brain rather than with one...|
|Next Article:||Gilead Sciences Inc (Foster City CA) said top-line results of a mid-stage study showed that its experimental drug regimen to treat HIV infection met...|